JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: Clinical Trial Support

Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis

Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis.  Lead author: Rodrigo E. Mendes, presented at IDWeek 2023, Oct 11-15, 2023, Boston, Massachusetts.

Poster #2785

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers.

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers. By Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK. Antimicrob. Agents Chemother. 63 (6): e02655, 2019.

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates.

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS)

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS). Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-633

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-452

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #326

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates.

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1328-1335

ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections

ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections, Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Beta-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates.

Beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN. published in Antimicrob. Agents. Chemother. 2015; 60 (3): 1328-1335

ß-Lactamase Characterization Enterobacteriaceae Baseline Pathogens from Two Phase 3 Trials of CAZ-AVI

ß-Lactamase Characterization Enterobacteriaceae Baseline Pathogens from Two Phase 3 Trials of CAZ-AVI, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole.

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole. by Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN and Flamm RK published in Microb. Drug Resist.: 2016; 22 (1): 53-58,

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli.

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli. by Mendes RE, Alley MR, Sader HS, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (6): 2849-2857

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia.

Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia. by Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ and Jones RN published in J. Clin. Microbiol. 2012; 50 (11): 3694-3702

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. by Farrell DJ, Turner LL, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (1): 73-74

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid.

Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from Phase IV clinical trial for linezolid. by Mendes RE, Sader HS, Deshpande LM, Diep BA, Chamers HF, Jones RN published in J. Clin. Microbiol. 2010; 48 (2): 568-574

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections.

Molecular characterization of Staphylococcus aureus isolates from a 2005 clinical trial of uncomplicated skin and skin structure infections. by Jones RN, Nilius AM, Akinlade BK, Deshpande LM and Notario GF published in Antimicrob. Agents Chemother. 2007; 51 (9): 3381-3384

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES).

Safety and efficacy of gatifloxacin in community-acquired pneumonia: Rationale for the Tequin Clinical Experience Study (TeqCES). by Mandell LA published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 65-67

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5,889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5,889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. by Jones RN, Pfaller MA, Fuchs PC, Aldridge K, Allen SD, and Gerlach EH published in Diagn. Microbiol. Infect. Dis. 1989; 12 (6): 489-494